These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18680438)

  • 1. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.
    Lappin G; Stevens L
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1021-33. PubMed ID: 18680438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerator MS: its role as a frontline bioanalytical technique.
    Seymour MA
    Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in biomedical applications of accelerator mass spectrometry.
    Hah SS; Henderson PT; Turteltaub KW
    J Biomed Sci; 2009 Jun; 16(1):54. PubMed ID: 19534792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMS method validation for quantitation in pharmacokinetic studies with concomitant extravascular and intravenous administration.
    Lappin G; Seymour M; Young G; Higton D; Hill HM
    Bioanalysis; 2011 Feb; 3(4):393-405. PubMed ID: 21338259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of accelerator MS in pediatric drug evaluation.
    Vuong LT; Blood AB; Vogel JS; Anderson ME; Goldstein B
    Bioanalysis; 2012 Aug; 4(15):1871-82. PubMed ID: 22943618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of an intravenous microdose of 14C-labeled drug and accelerator mass spectrometry to measure absolute oral bioavailability in dogs; cross-comparison of assay methods by accelerator mass spectrometry and liquid chromatography-tandem mass spectrometry.
    Miyaji Y; Ishizuka T; Kawai K; Hamabe Y; Miyaoka T; Oh-hara T; Ikeda T; Kurihara A
    Drug Metab Pharmacokinet; 2009; 24(2):130-8. PubMed ID: 19430168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding value through accelerator mass spectrometry-enabled first in human studies.
    Seymour MA
    J Labelled Comp Radiopharm; 2016 Dec; 59(14):640-647. PubMed ID: 27444819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.
    Sarapa N; Hsyu PH; Lappin G; Garner RC
    J Clin Pharmacol; 2005 Oct; 45(10):1198-205. PubMed ID: 16172185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study.
    Spracklin DK; Chen D; Bergman AJ; Callegari E; Obach RS
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):428-434. PubMed ID: 32562380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom.
    Barker J; Garner RC
    Rapid Commun Mass Spectrom; 1999; 13(4):285-93. PubMed ID: 10097404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of isotopes in the determination of absolute bioavailability of drugs in humans.
    Lappin G; Rowland M; Garner RC
    Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):419-27. PubMed ID: 16863443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
    Lappin G; Kuhnz W; Jochemsen R; Kneer J; Chaudhary A; Oosterhuis B; Drijfhout WJ; Rowland M; Garner RC
    Clin Pharmacol Ther; 2006 Sep; 80(3):203-15. PubMed ID: 16952487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An AMS method to determine analyte recovery from pharmacokinetic studies with concomitant extravascular and intravenous administration.
    Lappin G; Seymour M; Young G; Higton D; Hill HM
    Bioanalysis; 2011 Feb; 3(4):407-10. PubMed ID: 21338260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of accelerator mass spectrometry for pharmacological and toxicological research.
    Brown K; Tompkins EM; White IN
    Mass Spectrom Rev; 2006; 25(1):127-45. PubMed ID: 16059873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.
    Bae SK; Shon JH
    Arch Pharm Res; 2011 Nov; 34(11):1789-98. PubMed ID: 22139681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of accelerator mass spectrometry to obtain early human ADME/PK data.
    Lappin G; Garner RC
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):23-31. PubMed ID: 16922650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanotracing and cavity-ring down spectroscopy: A new ultrasensitive approach in large molecule drug disposition studies.
    Kratochwil NA; Dueker SR; Muri D; Senn C; Yoon H; Yu BY; Lee GH; Dong F; Otteneder MB
    PLoS One; 2018; 13(10):e0205435. PubMed ID: 30332475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attomole detection of 3H in biological samples using accelerator mass spectrometry: application in low-dose, dual-isotope tracer studies in conjunction with 14C accelerator mass spectrometry.
    Dingley KH; Roberts ML; Velsko CA; Turteltaub KW
    Chem Res Toxicol; 1998 Oct; 11(10):1217-22. PubMed ID: 9778319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Techniques: the application of accelerator mass spectrometry to pharmacology and toxicology.
    White IN; Brown K
    Trends Pharmacol Sci; 2004 Aug; 25(8):442-7. PubMed ID: 15276714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Accelerator Mass Spectrometry-Enabled Microtracer Study to Evaluate the First-Pass Effect on the Absorption of YH4808.
    Kim A; Yu BY; Dueker SR; Shin KH; Kim HS; Ahn H; Cho JY; Yu KS; Jang IJ; Lee H
    Clin Pharmacol Ther; 2017 Sep; 102(3):537-546. PubMed ID: 28214288
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.